Stephenson Harwood Advised Shield Therapeutics on Exclusive Japan Licence Agreement With VITAL-NET

Stephenson Harwood Advised Shield Therapeutics on Exclusive Japan Licence Agreement with VITAL-NET

Stephenson Harwood LLP has advised Shield Therapeutics plc on its exclusive licence agreement with VITAL-NET, Inc. for ACCRUFeR® in Japan.

Shield Therapeutics will receive an initial payment of approximately $665,000 and is eligible to receive additional milestone payments related to the regulatory approval of ACCRUFeR® and upon the achievement of specified net sales targets by VITAL-NET. For the term of the agreement, Shield will also receive double-digit royalties on net sales of ACCRUFeR®. VITAL-NET, Inc., a pharmaceutical wholesaler, will undertake and be responsible for all costs, including clinical and regulatory, related to activities required to achieve marketing authorisation and commercialisation of ACCRUFeR® in Japan.

Shield Therapeutics, a commercial-stage speciality pharmaceutical company focused on addressing iron deficiency, is meeting its commitment to expand its global footprint with this agreement. Japan is the third-largest pharmaceutical market worldwide and faces significant health challenges with iron deficiency prevalent among women, children, and the elderly. ACCRUFeR® offers a new option for those who need a more effective treatment to restore their iron levels and improve their overall health.

The team was led by Alexandra Pygall (Partner – Intellectual Property and Head of Life Sciences & Healthcare).

Click to know more about Stephenson Harwood

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.